Oxipit

Oxipit is a medical imaging company based in Vilnius, Lithuania, that develops artificial intelligence (AI) applications for diagnostic medical imaging. The company's flagship product, ChestLink, is the first autonomous AI medical imaging application that can produce finalized chest X-ray reports without any radiologist involvement for cases where it is highly confident that the study is normal. ChestLink received CE Class IIb certification in April 2022, allowing its deployment across European markets.

Another key product from Oxipit is ChestEye, an AI-powered radiology software suite that provides automated AI-based diagnosis and reporting for 75 common radiological findings in chest X-rays. By enabling radiologists to improve productivity, reduce error rates, and address the global shortage of radiology specialists, ChestEye aims to enhance the quality of medical diagnostics.

Oxipit's products leverage cutting-edge AI and machine learning algorithms developed by a team of award-winning data scientists and medical professionals. The company's solutions have undergone rigorous clinical validation trials, consistently achieving sensitivity rates exceeding 99% in identifying normal chest X-ray studies.

In addition to ChestLink and ChestEye, Oxipit offers Oxipit Quality, an AI-powered imaging audit tool that retrospectively analyzes radiologists' reports and corresponding medical images to identify potential errors or discrepancies. This product aims to improve diagnostic performance and patient outcomes by serving as a safety net for radiologists.